News | February 08, 2025
Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Q3 FY25 revenue up 24% to Rs 3,230 crore
Subscribe To Our Newsletter & Stay Updated
